Takeda Pharmaceutical Company Limited





Market Closed - Japan Exchange 02:00:00 2024-07-12 EDT 5-day change 1st Jan Change
4,298 JPY -0.32% Intraday chart for Takeda Pharmaceutical Company Limited +1.30% +6.02%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Takeda Issues New Shares, Disposes of Treasury Shares Under Incentive Scheme MT
Blackstone selling Japan drugmaker Alinamin to MBK Partners RE
Koru Medical Systems' FreedomEdge System Receives Regulatory Approval in Japan MT
KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in Japan CI
Codexis Sells Fabry, Pompe Disease Compounds to Crosswalk Therapeutics MT
Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited. CI
Transcript : Takeda Pharmaceutical Company Limited - Shareholder/Analyst Call
US CDC alerts healthcare providers of increase in dengue cases RE
Takeda's Cancer Drug Gets European Commission Approval MT
Hutchmed China notes Takeda obtains EU approval for Fruzaqla AN
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators MT
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment MT
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare CI
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts MT
Takeda Receives European Commission Approval for Colorectal Cancer Treatment MT
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib) CI
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia CI
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla MT
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment DJ
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer CI
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes MT
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India RE
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India MT
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India CI
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP MT
Chart Takeda Pharmaceutical Company Limited
More charts
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
4,298 JPY
Average target price
4,744 JPY
Spread / Average Target
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. News Takeda Pharmaceutical Company Limited
  5. Takeda Signs Option Agreement with Ascentage to License Leukemia Drug